Welcome to our dedicated page for PetVivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PetVivo Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PetVivo Holdings's regulatory disclosures and financial reporting.
PetVivo Holdings, Inc. reported unaudited results for the three months ended June 30, 2026. Revenue was $337,572, up from $297,500 a year earlier, driven largely by distributor Vedco, which accounted for about 70% of sales, and Clipper, at about 12%.
Gross profit was $223,317. Operating expenses were $1,832,166, leading to an operating loss of $1,608,849 and a net loss of $1,613,888, an improvement versus a $2,311,037 net loss in the prior-year quarter. Net cash used in operating activities was $965,779. Cash declined to $122,633 and total assets to $2,669,481, with stockholders’ equity of $1,356,169 and an accumulated deficit of $103,051,394.
The company corrected prior accounting for a June 30, 2025 convertible note amendment by removing a $763,259 beneficial conversion feature in line with ASU 2020‑06; this changed equity classifications but did not affect prior revenue or net loss. Management concluded that recent losses, low cash, and dependence on external financing raise substantial doubt about the ability to continue as a going concern. Subsequent events include additional non-convertible debt financing and formal termination of the VetStem PrecisePRP licensing agreement.
PetVivo Holdings, Inc. shareholder Alexander Nazarenko reports beneficial ownership of 8,044,085 PetVivo securities, representing 18.73% of the issuer’s outstanding common and preferred shares as of July 22, 2026. This includes 2,045,081 shares with sole voting and dispositive power and 5,999,004 shares with shared voting and dispositive power, held directly, by his spouse, and through entities he controls. He also holds 1,011,985 warrants that are currently excluded from the ownership calculation under SEC Rule 13d-3(d)(1). Nazarenko states the holdings were not acquired for the purpose of changing or influencing control of PetVivo and that he is not the beneficial owner of 20% or more of the class.
PetVivo Holdings, Inc. reported a change in its independent auditors. Stephano Slack LLC resigned as the company’s independent registered public accounting firm, effective July 2, 2026, after auditing the fiscal years ended March 31, 2026 and March 31, 2025. Those audit reports contained no adverse or disclaimed opinions and were not qualified, but the 2026 report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, which is treated as a reportable event. The company states there were no disagreements with Stephano Slack on accounting or auditing matters.
On July 23, 2026, with Audit Committee approval, PetVivo engaged GuzmanGray, A Professional Accountancy Corporation, as its new independent registered public accounting firm for the fiscal year ending March 31, 2027, including interim review periods ending June 30, September 30, and December 31, 2026. PetVivo reports it had not previously consulted GuzmanGray on accounting, auditing, or financial reporting issues.
PetVivo Holdings, Inc. reported that Chief Financial Officer Garry N. Lowenthal indirectly acquired 75,000 shares of restricted common stock on 2026-07-21 at $0.77 per share. The grant was issued to a corporation he owns as compensation for past performance, bringing his indirect "By Corporation" holdings to 953,881 shares.
Lai John reported acquisition or exercise transactions in this Form 4 filing.
PetVivo Holdings, Inc. reported that Chief Executive Officer John Lai, through a corporation he owns, received a grant of 75,000 shares of restricted common stock on July 21, 2026 at $0.77 per share as compensation for past performance, increasing his indirectly held common stock to 2,381,913 shares.
PetVivo Holdings, Inc. files its annual report describing an emerging veterinary medical device business built around Spryng, an injectable joint treatment for osteoarthritic dogs and horses. The company reported an approximate $10 million net loss for the year ended March 31, 2026 and an accumulated deficit of about $102.0 million.
Liquidity is a key concern: cash and cash equivalents were roughly $201,000 as of March 31, 2026, which management expects to fund operations for about one month, or roughly four months if up to $1.5 million is invested under an existing purchase option. As of June 29, 2026, non‑affiliate common stock had an aggregate market value of $12,126,991, with 37,594,245 shares outstanding. The report emphasizes dependence on Spryng, new distribution relationships with Vedco and Clipper, an exclusive licensing deal for VetStem’s PrecisePRP, and a portfolio of patents, trade secrets, and trademarks. Extensive risk factors highlight continuing losses, financing needs, prior Nasdaq delisting and trading on OTCQX, strong competition in animal health, manufacturing and distribution risks, and cybersecurity oversight processes.
PetVivo Holdings has signed an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM) in an all‑stock transaction. PBM will merge into a PetVivo subsidiary and, after closing, operate as a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials-focused operating arm.
PBM shareholders are slated to receive an aggregate of 3,000,000 shares of PetVivo restricted common stock. A first block of up to 1,500,000 shares will be fully vested at closing, while the remaining “Milestone Shares” will be issued but subject to forfeiture unless specified development and regulatory milestones are achieved.
Before closing, PBM must clear defined liabilities and convert or settle all preferred stock, SAFEs, options, warrants and other securities. Closing also depends on PetVivo completing an equity financing with at least $5.0 million in gross proceeds. PBM’s extensive intellectual property portfolio will remain in PBM, and key PBM personnel are expected to stay involved through consulting and service arrangements.
PetVivo Holdings, Inc. major holder A.L. Sarroff Fund, LLC reported open-market purchases tied to unit financing. The fund bought 187,500 shares of Common Stock and 187,500 Warrants, with each Unit priced at $0.80 and consisting of one share plus one Warrant.
The Warrants allow purchase of 187,500 shares of Common Stock at an exercise price of $1.10 per share until June 9, 2036. Following the transactions, the fund holds 10,439,729 shares of Common Stock and 187,500 Warrants directly, indicating a modest incremental increase in its position.
A.L. Sarroff Fund, LLC, a 10% owner of PetVivo Holdings, Inc., reported a bona fide gift transfer of 200,000 shares of common stock on May 28, 2026. The transfer was recorded at $0.00 per share, and the fund now directly holds 10,252,229 shares. Alan L. Sarroff, as Chief Executive Officer and Managing Member of the fund, is deemed to beneficially own these securities with sole voting and dispositive power.
PetVivo Holdings, Inc. saw its significant shareholder A.L. Sarroff Fund, LLC make an open-market purchase of common stock. On May 22, 2026, the fund bought 250,000 shares at 0.40 per share, increasing its direct holdings to 10,452,229 shares.
Alan L. Sarroff, as Chief Executive Officer and Managing Member of A.L. Sarroff Fund, is deemed to beneficially own these securities and to have sole voting and dispositive power over them. This transaction modestly increases an already large position in the company.